



The Manager
Company Announcements Office
Australian Stock Exchange
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

8 March 2022

Dear Manager,

IRESS LIMITED –APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR

Please find attached an Appendix 3Y announcement relating to the vesting of 67,057 performance rights awarded in 2019 and 76,374 equity rights awarded in 2020 to Andrew Walsh, CEO & Managing Director.

Yours sincerely

A handwritten signature in blue ink, appearing to be "PF" followed by a long horizontal stroke.

Peter Ferguson
Chief Legal Officer & Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Iress Limited
ABN	47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Walsh
Date of last notice	31 August 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect										
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect through Salernes Pty Ltd ATF Walsh Family Trust										
Date of change	2 March 2022										
No. of securities held prior to change	<p><u>Ordinary Shares</u></p> <table> <tr> <td>Direct:</td> <td style="text-align: right;">476,455</td> </tr> <tr> <td>Indirect:</td> <td style="text-align: right;"><u>136,791</u></td> </tr> <tr> <td></td> <td style="text-align: right;">613,246</td> </tr> </table> <p><u>Unvested Share/Rights Grants Overview:</u></p> <table> <tr> <td>Deferred Share Rights all Series:</td> <td style="text-align: right;">42,736</td> </tr> <tr> <td>Performance Rights pre-2019 Series:</td> <td style="text-align: right;">91,210</td> </tr> </table>	Direct:	476,455	Indirect:	<u>136,791</u>		613,246	Deferred Share Rights all Series:	42,736	Performance Rights pre-2019 Series:	91,210
Direct:	476,455										
Indirect:	<u>136,791</u>										
	613,246										
Deferred Share Rights all Series:	42,736										
Performance Rights pre-2019 Series:	91,210										

+ See chapter 19 for defined terms.

	<p><u>Unvested Rights/Grants under revised 2019 executive remuneration framework:</u></p> <p>Equity Rights: 173,463 Performance Rights: 263,799</p> <p>Unvested Share/Rights Grants Details:</p> <p>2018 Series Performance Rights 2018:</p> <ul style="list-style-type: none"> • 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 • 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 <p>2019 Series Deferred Shares Rights 2019:</p> <ul style="list-style-type: none"> • 3 year term, granted 9 May 2019: - 42,736 <p><u>2019 Series – New Framework</u></p> <p>Performance Rights 2019:</p> <ul style="list-style-type: none"> • 3 year term, granted 9 May 2019: – 80,020 <p><u>2020 Series – New Framework</u> Equity Rights 2020:</p> <ul style="list-style-type: none"> • 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2022, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 Feb 2022 – 28 Feb 2024): – 76,374 <p>Performance Rights 2020:</p> <ul style="list-style-type: none"> • 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916 <p><u>2021 Series - New Framework</u> Equity Rights 2021:</p> <ul style="list-style-type: none"> • 2 year term, granted in May 2021, 2 year measurement period commencing 28 Feb 2021 - 28 Feb 2023. Shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 Feb 2023 - 28 Feb 2025) - 97,089 <p>Performance Rights 2021:</p> <ul style="list-style-type: none"> • 3 year term, granted in May 2021, 3 year measurement period commencing 1 Jan 2021 - 31 Dec 2024: - 102,863
Class	Ordinary

+ See chapter 19 for defined terms.

Number acquired	<u>Ordinary Shares</u> Direct: Nil Indirect: 143,431
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Average price per share \$10.4415
No. of securities held after change	<p><u>Ordinary Shares</u></p> Direct: 476,455 Indirect: <u>280,222</u> 756,677
	<p><u>Unvested Share/Rights Grants Overview:</u></p> <p>Deferred Share Rights all Series: 42,736</p> <p>Performance Rights pre-2019 Series: 91,210</p> <p><u>Unvested Rights/Grants under revised 2019 executive remuneration framework:</u></p> <p>Equity Rights: 97,089 Performance Rights: 183,779</p> <p>Unvested Share/Rights Grants Details:</p> <p>2018 Series Performance Rights 2018: <ul style="list-style-type: none"> 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 </p> <p>2019 Series Deferred Shares Rights 2019: <ul style="list-style-type: none"> 3 year term, granted 9 May 2019: - 42,736 </p> <p><u>2020 Series – New Framework</u></p> <p>Performance Rights 2020: <ul style="list-style-type: none"> 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916 </p>

+ See chapter 19 for defined terms.

	<p><u>2021 Series - New Framework</u></p> <p>Equity Rights 2021:</p> <ul style="list-style-type: none"> 2 year term, granted in May 2021, 2 year measurement period commencing 28 Feb 2021 - 28 Feb 2023. Shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 Feb 2023 - 28 Feb 2025) - 97,089 <p>Performance Rights 2021:</p> <ul style="list-style-type: none"> 3 year term, granted in May 2021, 3 year measurement period commencing 1 Jan 2021 - 31 Dec 2024: - 102,863
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Partial vesting and partial lapsing of 2019 Performance Rights after testing:</p> <ul style="list-style-type: none"> 3 year measurement period – 67,057 vested and 12,963 lapsed. <p>Vesting of 2020 Equity Rights:</p> <ul style="list-style-type: none"> 2 year measurement period – 76,374 vested

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change</p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A
-----------------------	-----

Part 3 – ⁺ Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.